A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicityMarta Compte, Luis Álvarez‐Vallina(Aarhus University)Nature CommunicationsNovember 9, 201810.1038/s41467-018-07195-wCited by 143SaveCiteExport RISWatch citationsRelated PapersATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy|OncoImmunology|2017|81